Open Access Green as soon as Postprint is submitted to ZB.
Regulatory challenges for look-alike and sound-alike non-biological complex drugs: Molecular fingerprint discrimination of Ichthammol formulations.
Mol. Pharm., DOI: 10.1021/acs.molpharmaceut.5c00679 (2025)
Look-alike and sound-alike (LASA) medications are a critical source of medication errors, posing significant risks to patient safety. This issue is particularly relevant for non-biological complex drugs (NBCDs), whose intricate compositions and manufacturing-dependent properties complicate regulatory assessment and comparability of follow-on products. In this study, we employ high-resolution mass spectrometry (HRMS) techniques, including Fourier-transform ion cyclotron resonance mass spectrometry (FT-ICR MS) and comprehensive two-dimensional gas chromatography coupled to high-resolution time-of-flight mass spectrometry (GC×GC-HRToF MS), to differentiate between Ichthammol formulations compliant with different pharmacopeia definitions. Despite similar bulk properties, comprehensive molecular-level characterization reveals substantial compositional differences: European Pharmacopeia (Ph. Eur.) compliant samples, which also largely correspond to the U.S. pharmacopeia (USP), predominantly contain sulfonated thiaarenes derived from shale oil, while samples compliant with the Chinese Pharmacopeia (ChP) consist mainly of sulfurized fatty acids and sulfur-linked fatty acid oligomers derived from vegetable oils. Proposed reaction mechanisms describe a classical aromatic sulfonation by sulfuric acid yielding ammonium sulfonates of thiaarenes and, in smaller quantities, ammonium sulfonate arenes in the Ph. Eur. formulations after neutralization with ammonia. In contrast, ChP formulations likely undergo an initial sulfurization via vulcanization, leading to thiophene-containing fatty acids and sulfur-linked oligomers, followed by sulfonation and neutralization. Our findings provide strong evidence for distinct chemical fingerprints, allowing robust differentiation between these complex LASA drugs. These findings were in accordance with the mechanistic pathways for their respective manufacturing processes proposed in this study. These insights highlight the necessity of molecular-level analysis for regulatory assessment of complex pharmaceuticals and underscore the potential risks of relying solely on bulk parameter equivalence in complex drug approval and substitution.
Impact Factor
Scopus SNIP
Altmetric
4.500
0.000
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Follow-on Products ; Gas Chromatography ; Generics ; High-resolution Mass Spectrometry ; Look-alike Sound-alike (lasa) ; Non-biological Complex Drug (nbcd) ; Pharmaceuticals ; Shale Oil; Mass-spectrometry; Products; Oils
Language
english
Publication Year
2025
HGF-reported in Year
2025
ISSN (print) / ISBN
1543-8384
e-ISSN
1543-8392
Journal
Molecular Pharmaceutics
Publisher
American Chemical Society (ACS)
Publishing Place
1155 16th St, Nw, Washington, Dc 20036 Usa
Reviewing status
Peer reviewed
POF-Topic(s)
30202 - Environmental Health
Research field(s)
Environmental Sciences
PSP Element(s)
G-504500-001
Grants
Ichthyol-Gesellschaft Cordes, Hermanni & Co. (GmbH Co.) KG
Ichthyol-Gesellschaft Cordes, Hermanni & Co. (GmbH Co.) KG
WOS ID
001604986100001
PubMed ID
41161732
Erfassungsdatum
2025-10-31